Zoetis Inc.

Zoetis Inc. is a global animal health company based in Parsippany, New Jersey, with a diversified business in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for animals. The company was incorporated in Delaware in 2012 and has a workforce of approximately 10,700 employees. Zoetis operates in two segments: United States (53% of total revenue) and International (46% of total revenue). The company's business strategy focuses on developing a diverse portfolio of animal health products for companion animals and livestock, with a strong emphasis on innovation and continuous improvement. Zoetis offers a range of products and services across eight core species and seven major product categories, including parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. The company's website is zoetis.com, and its ticker symbol is ZTS. The company's major product categories include parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. Some of its notable products include Apoquel for dogs, Core EQ Innovator for horses, Cytopoint for dogs, Fostera for pigs, Librela for dogs, ProHeart for dogs, Revolution for cats and dogs, Simparica for dogs, Cerenia for dogs and cats, Rimadyl for dogs, and Solensia for cats. Zoetis has a global manufacturing network of 29 sites, including sites operated by the company and third-party contract manufacturing organizations (CMOs). The company's sales and marketing efforts are focused on building strong relationships with veterinarians, livestock producers, and pet owners, as well as investing in direct-to-consumer marketing efforts in certain markets. The company's R&D efforts are focused on developing new products and continuously improving existing ones, with a commitment to product lifecycle innovation and regulatory maintenance. Zoetis also collaborates with external parties on research programs and gains access to substrates and technologies through partnerships.